Third-Line Treatment Options for Metastatic Colorectal Cancer - Episode 5

Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

December 5, 2024

Marwan G. Fakih, MD, City of Hope, Nilo Azad, MD

Panelists discuss how health-related quality of life (HRQOL) data influence their treatment decisions for third-line metastatic colorectal cancer (mCRC), how they assess patient symptoms and quality of life in clinical practice, and how the toxicity profiles of different therapies guide their treatment choices.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Navigating mCRC: Treatment Options in the Third-Line Setting

EP. 2: Nuances With Defining “Refractory” mCRC in the Third-Line Setting

EP. 3: Treatment Sequencing in mCRC: Balancing Expert Perspectives and Shared Decision-Making With Patients

EP. 4: Perspectives on the SUNLIGHT Trial: Study Design and Outcomes

Now Viewing

EP. 5: Factoring in Health-Related Quality of Life Outcomes in mCRC Treatment Selection

EP. 6: Navigating Toxicities: Trifluridine-Tipiracil Plus Bevacizumab

EP. 7: Dosing Trifluridine-Tipiracil (TAS-102) Plus Bevacizumab Considerations: Hepatic or Renal Impairment

EP. 8: Unmet Needs in Third-Line mCRC: Challenges and Opportunities

How do the reported HRQOL data influence your treatment decisions? And how do you assess your patient’s symptoms or quality of life in a real-life practice setting?
How does the toxicity profile of each agent influence your treatment selection?